Faeth Therapeutics Reports $186.2 Million Net Loss and Significant Asset Growth in Latest Filing

Faeth Therapeutics, Inc. (formerly Sensei Biotherapeutics, Inc.) reported significant financial developments in its latest 10-Q filing for the quarter ending June 30, 2026. The company recorded a net loss of $186.2 million for the first half of 2026, a substantial increase from a net loss of $11.8 million during the same period in 2025. This increase is primarily attributed to $133 million in acquired in-process research and development expenses related to the acquisition of Faeth Holdings Therapeutics, which was completed on February 17, 2026. Total operating expenses for the six months ended June 30, 2026, reached $189 million, compared to $12.5 million in the prior year.

The company’s financial position has markedly improved following the acquisition, with total assets increasing to $189.3 million as of June 30, 2026, up from $22.9 million at the end of 2025. This growth is largely due to the acquisition and a successful private placement that raised $200 million in gross proceeds. Cash and cash equivalents rose to $26.9 million, alongside marketable securities valued at $159.5 million, providing a solid liquidity position to support ongoing operations and clinical trials.

Operationally, Faeth Therapeutics is focused on advancing its lead program, PIKTOR, an investigational therapy targeting the PI3K/AKT/mTOR pathway, which is currently in Phase 2 trials for advanced endometrial cancer. The company has also initiated a Phase 1b/2 trial for HR+/HER2- advanced breast cancer. The integration of Faeth's operations has led to increased research and development expenses, which totaled $27.1 million for the first half of 2026, compared to $6.3 million in the previous year. General and administrative expenses also surged to $28.9 million, reflecting the costs associated with the acquisition and the expansion of the workforce.

Looking ahead, Faeth Therapeutics anticipates continued operating losses as it invests in the development of its product candidates. The company expects its existing cash, cash equivalents, and marketable securities will be sufficient to fund operations through key clinical milestones, including topline data readouts from ongoing trials. However, the company acknowledges the need for additional financing to support its long-term strategy, which may involve equity offerings, debt financing, or strategic collaborations. As of June 30, 2026, Faeth had an accumulated deficit of $469.4 million, underscoring the financial challenges typical of early-stage biotechnology firms.